From Yahoo Finance: 2025-06-14 04:40:00

Eli Lilly, a growth company since the late 1800s, has seen its stock drop by 6.4% in the last year. However, this dip is seen as a buying opportunity due to the success of its weight-loss drugs, Mounjaro and Zepbound, both now classified as blockbuster drugs. The company’s first-quarter sales have been strong, driven by these products, and a new daily oral treatment for diabetes and weight loss is in the works. Eli Lilly’s total revenue grew by 45% year over year, with management expecting further growth and EPS increase. Despite a high P/E ratio, the stock’s above-average valuation is justified by its rapid earnings growth and potential new products.



Read more at Yahoo Finance: 1 Growth Stock Down 9% to Buy Right Now